Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy in the treatment of anal canal carcinoma.
Cacheux W, Lievre A, De La Rochefordiere A, Dieumegard B, Cvitkovic F, Labib A, Mitry E, Buecher B. Cacheux W, et al. Among authors: de la rochefordiere a. Dig Liver Dis. 2012 Oct;44(10):803-11. doi: 10.1016/j.dld.2012.04.013. Epub 2012 May 30. Dig Liver Dis. 2012. PMID: 22658644 Review.
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Cacheux W, Rouleau E, Briaux A, Tsantoulis P, Mariani P, Richard-Molard M, Buecher B, Dangles-Marie V, Richon S, Lazartigues J, Jeannot E, Farkhondeh F, Sastre-Garau X, de La Rochefordière A, Labib A, Falcou MC, Stevens D, Roth A, Roman-Roman S, Mitry E, Bièche I, Lièvre A. Cacheux W, et al. Among authors: de la rochefordiere a. Br J Cancer. 2016 Jun 14;114(12):1387-94. doi: 10.1038/bjc.2016.144. Epub 2016 May 24. Br J Cancer. 2016. PMID: 27219019 Free PMC article.
Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first.
Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A. Bollet MA, et al. Among authors: de la rochefordiere a. Radiother Oncol. 2007 Mar;82(3):272-80. doi: 10.1016/j.radonc.2007.01.001. Epub 2007 Feb 6. Radiother Oncol. 2007. PMID: 17287037
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A. Kirova YM, et al. Among authors: de la rochefordiere a. Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Breast Cancer Res Treat. 2010. PMID: 20033769 Review.
Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study.
de la Rochefordiere A, Kirova Y, Alran S, Plancher C, Fourchotte V, Beuzeboc P, de Margerie V, Petrow P, Sastre-Garau X, Servois V, Scholl S, Cottu P, Mignot L, de Cremoux P, Salmon R. de la Rochefordiere A, et al. Among authors: de margerie v, de cremoux p. Clin Med Oncol. 2008;2:227-36. doi: 10.4137/cmo.s489. Epub 2008 Mar 27. Clin Med Oncol. 2008. PMID: 21892284 Free PMC article.
Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D; Institut Curie Breast and Ovarian Cancer Risk Study Group. This P, et al. Among authors: de la rochefordiere a. Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1. Fam Cancer. 2012. PMID: 22711610 Clinical Trial.
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D. Deutsch E, et al. Ann Oncol. 2013 Nov;24(11):2834-8. doi: 10.1093/annonc/mdt368. Epub 2013 Sep 11. Ann Oncol. 2013. PMID: 24026540 Free article. Clinical Trial.
Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.
Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Leclercq J, Juzyna B, Ezra P, Lemanski C, Deutsch E. Levy A, et al. Radiother Oncol. 2015 Mar;114(3):415-6. doi: 10.1016/j.radonc.2015.02.008. Epub 2015 Mar 11. Radiother Oncol. 2015. PMID: 25769380 No abstract available.
Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature.
Bazire L, Xu H, Foy JP, Amessis M, Malhaire C, Cao K, De La Rochefordiere A, Kirova YM. Bazire L, et al. Among authors: de la rochefordiere a. Br J Radiol. 2017 May;90(1073):20160885. doi: 10.1259/bjr.20160885. Epub 2017 Mar 14. Br J Radiol. 2017. PMID: 28291401 Free PMC article. Review.
69 results